NIAID Media Availability

Barrier in Mosquito Midgut Protects Invading Pathogens

Discovery May Inform New Strategies for Blocking Malaria Transmission

What:

Scientists studying the Anopheles gambiae mosquito —
the main vector of malaria — have found that when the mosquito
takes a blood meal, that act triggers two enzymes to form a network
of crisscrossing proteins around the ingested blood. The formation
of this protein barrier, the researchers found, is part of the normal
digestive process that allows so-called "healthy" or commensal
gut bacteria to grow without activating mosquito immune responses.
But there is a downside: The barrier also prevents the mosquito's
immune defense system from clearing any disease-causing agents that
may have slipped into the blood meal, such as the Plasmodium malaria
parasite, which in turn can be passed on to humans.

Disrupting the protein barrier, however, can trigger mosquito immune defenses to intervene and protect the insect from infection, notes the research team from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The enzymes involved in the protein barrier are called immunomodulatory peroxidase (IMPer) and dual oxidase (Duox). The researchers believe it might be possible to prevent the formation of the protein barrier by immunizing people with IMPer or the proteins that crisscross. This vaccine would generate antibodies that, after a mosquito feeds on a human, could disrupt the barrier, reduce parasite survival in the mosquito and prevent malaria transmission.

The role of IMPer-Duox in forming a protective barrier was unexpected — and previously unrecognized, according to Carolina Barillas-Mury, M.D., Ph.D., the senior study author. When her research group silenced, or turned off, the gene for either IMPer or Duox, the mosquito's midgut immune system took over and greatly reduced Plasmodium infection, indicating that IMPer and Duox are both required for parasite survival.

The IMPer-Duox system also is found in the mucous membrane of some human tissues, such as the colon. Dr. Barillas-Muryís group is investigating whether a protective protein barrier similar to that seen in mosquitoes also forms in vertebrates, including humans. If so, the barrier could be part of the process that normally prevents the colon from activating immune responses against commensal bacteria, as this would be harmful and lead to chronic inflammation. The existence of such a barrier in humans could have broad implications for the prevention and treatment of diseases such as chronic inflammatory bowel disease.

Carolina Barillas-Mury, M.D., Ph.D., chief of the Mosquito Immunity and Vector Competence Unit in NIAIDís Laboratory of Malaria and Vector Research, is available to comment on this article.

NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers
and is a component of the U.S. Department of Health and Human Services. NIH
is the primary federal agency conducting and supporting basic, clinical, and
translational medical research, and is investigating the causes, treatments,
and cures for both common and rare diseases. For more information about NIH
and its programs, visit http://www.nih.gov.